Treatment for Eradication of Helicobacter pylori Infection among Chronic Hepatitis C Patients

Abstract

Background/AimsHelicobacter pylori infection causes gastritis, peptic ulcers and gastric malignancies, and its eradication has been advocated by many groups. We determined the H. pylori carrier status and eradication rates of patients with chronic hepatitis C virus (HCV) infection.MethodsIn total, 76 chronically HCV-infected patients were enrolled for comparison with 228 HCV-noninfected, age- and sex-matched controls. H. pylori infection was confirmed by H. pylori antibody and urea breath testing.ResultsThe H. pylori infection rate was significantly higher for HCV-infected patients (67 of 76, 88.2%) than for HCV-noninfected controls (158 of 228, 69.3%). Endoscopic findings showed that the rates of gastric ulcers and gastritis were significantly higher for the 67 HCV-infected patients with H. pylori infection (34.3% and 77.6%) than for the 158 HCV-noninfected controls with H. pylori infection (15.2% and 57.6%). Treatment to eradicate H. pylori had a significantly higher success rate for HCV-infected patients (61 of 67, 91.0%) than for HCV-noninfected controls (115 of 158, 72.8%).ConclusionsThe markedly high H. pylori eradication rate observed in this study shows that eradication of H. pylori holds promise for the improvement of the long-term health condition of patients with chronic HCV infection.

Evaluation of Noninvasive Versus Invasive Techniques for the Diagnosis of Helicobacter pylori Infection

“…32 For example, in an epidemiologic western study conducted in the United States, primary gastric MALT lymphoma represented approximately 12% of the extranodal non-Hodgkin lymphomas that occurred among men and approximately 18% of extranodal non-Hodgkin lymphomas among women, and during the period 1999 to 2003 the annual incidence in the United States was about 1 case for every 100,000 individuals in the population. 35 In an Egyptian study, El-Masry et al 36 reported that H. pylori positivity increased significantly (P = 0.03) in HCV-infected patients when compared with healthy controls: H. pylori infection was found in 50 (55.6%) of 90 HCV-infected patients versus 26 (39.4%) of 66 healthy controls. The standardized incidence rates in Saarland and Franconia were 0.7 and 0.8 cases per 100,000, respectively.…”

“…31 In a series on 208 Egyptian patients with primary gastrointestinal lymphomas, the stomach was the main site of involvement, constituting approximately 75% of cases, a figure clearly higher than in many other published series. 34 It is noteworthy to highlight the results of a recent study focusing on coinfection with hepatitis C virus (HCV) and H. pylori, in which Furusyo et al 35 reported that H. pylori infection rate was significantly higher for HCV-infected patients (67 of 76, 88.2%) than for HCVnoninfected controls (158 of 228, 69.3%). 33 Also in a population-based study in Germany and over a period of 3 years, 94 patients with primary gastric lymphoma were recorded out of a total population of 3.5 million.…”

The efficiency and safety of anti-Helicobacter pylori therapy in patients with concomitant chronic hepatitis C

“…Согласно различным исследованиям, частота развития сочетанной инфекции H. pylori и HCV высока и достигает 73,1-88,6%, что определяет большую вероятность развития ассоциированных с H. pylori заболеваний в этой группе пациентов [7][8][9]. При этом аспекты влияния сопутствующей HCV-инфекции на эффективность и безопасность эрадикационной терапии (ЭТ) инфекции H. pylori изучены мало.…”

“…При этом аспекты влияния сопутствующей HCV-инфекции на эффективность и безопасность эрадикационной терапии (ЭТ) инфекции H. pylori изучены мало. В литературе существует только одно исследование, проведенное в Японии, в котором оценивалось влияние сопутствующего хронического гепатита С (ХГС) на эффективность ЭТ инфекции H. pylori [8]. Авторы выявили более высокую эффективность лечения в когорте больных ХГС по сравнению с HCV-негативными лицами.…”

“…В рамках оценки влияния ФП на эффективность ЭТ во 2-й группе (HCV+) мы решили комбинировать стадии ФП по принципу F 0 +F 1 , F 2 +F 3 , F 4 для сопоставления результатов с работой N. Furusyo и соавт. [8]. Анализ результатов в этой группе пациентов показал фактически сопоставимую эффективность ЭТ.…”